X

Drug Profile

Research programme: CEB 1310 series - Vernalis

Alternative Names: CEB 1310 series research programme - Vernalis

Latest Information Update: 15 Aug 2000

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vernalis Group
Class
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Craniocerebral trauma; Psychotic disorders

Most Recent Events

15 Aug 2000 Discontinued-Preclinical for Head injuries in United Kingdom (Unknown route)
15 Aug 2000 Discontinued-Preclinical for Psychotic disorders in United Kingdom (Unknown route)
24 May 2000 Vanguard Medica is now called Vernalis Group

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com